AR054125A1 - Derivados del fluoreno, composiciones farmaceuticas que los contienen y su utilizacion en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de la proteina hsp90 - Google Patents
Derivados del fluoreno, composiciones farmaceuticas que los contienen y su utilizacion en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de la proteina hsp90Info
- Publication number
- AR054125A1 AR054125A1 ARP060101980A ARP060101980A AR054125A1 AR 054125 A1 AR054125 A1 AR 054125A1 AR P060101980 A ARP060101980 A AR P060101980A AR P060101980 A ARP060101980 A AR P060101980A AR 054125 A1 AR054125 A1 AR 054125A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- aryl
- heteroaryl
- heterocycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Uso de los mismos en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la proteína HSP9U y composiciones farmacéuticas que los contienen. Reivindicacion 1: Los productos de la formula (1), en la que: A1, A2, A3 y A4, idénticos o diferentes, representan CRa o N o NRb; en el cual Rb representa alquilo, alcoxi u OH; R1 y R1' son tales que: o bien R1 y R1' idénticos o diferentes son tales que uno de R1 y R1' representa un átomo de hidrogeno o de halogeno o un radical seleccionado entre alquilo C1-3, alcoxi C1-3, alquil-OH, CF3, ciano, carboxi y carboxamido; y el tro de R1 y R1' se selecciona del grupo constituido por H; halogeno; CF3; hidroxi; mercapto; nitro; amino; NH-OH ; NH-CO-H ; NH-CO-OH, NH-CO- Oalquilo, NH-CO-NH2; carboxi; CN; CO-NH2; X-(CH2)m-alquilo; X-(CH2)m-cicloalquilo; X-(CH2)m-heterocicloalquilo; X-(CH2)m-arilo o X-(CH2)m-heteroarilo con X = enlace sencillo, CH2, CH=CH, CH2-O, CH2-NH, CH2-C(O), CH2-C(O)-O, CH2-C(O)-NH, CH2-NH-(CO), CH2-NH-S(O), CH2- NH-S(O)2, O, S, NH, O-C(O), C(O)-NH1 -NH-C(O), -NH-C(O)-C(O)-, -NH-C(O)-NH-, NH-CS, NH-S(O) o NH-S(O)2, -NH-CO-CH2-O-; -NH-CO-CH2-S-CH2-CO-NH-; -NH-CO-(CH2)2-SO2-; -NH-CO-CH2-N(CH3)-CO-; con m = 0, 1 o 2, estando todos los radicales alquilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo opcionalmente sustituidos, conteniendo el radical cicloalquilo de 3 a 10 miembros, conteniendo el radical arilo de 6 a 10 miembros, y conteniendo los radicales heterocicloalquilo y heteroarilo, opcionalmente sustituidos, de 4 a 10 miembros de los cuales 1 a 4 son heteroátomos seleccionados entre O, S, N o NR3 en el cual R3 representa H o alquilo que está él mismo opcionalmente sustituido; o bien R1 y R'1 forman junto con los átomos de carbono a los cuales están unidos un radical =O; =S; =N-OH; =N-NH2; =N-NH-CO-NH2, =CH-OH; =Y1-(CH2)m-arilo o =Y1-(CH2)m-heteroarilo, en los cuales Y1 representa CH, CH-CO-, CH-CO-NH, N, N-O o N-NH, con m = 0, 1 o 2 y en los cuales arilo y heteroarilo son como se ha definido anteriormente y están opcionalmente sustituidos; o bien R1 R'1 forman junto con los átomos de carbono a los cuales están unidos un ciclo parcialmente saturado que consta de 4 a 6 miembros y que contiene eventualmente 1 a 3 heteroátomos seleccionados entre O, S, N o NR4 en el cual R4 representa H o alquilo que está él mismo opcionalmente sustituido; R2 y R'2, idénticos o diferentes, se seleccionan independientemente del grupo constituido por H, halogeno, CF3, nitro, ciano, alquilo, hidroxi, mercapto, amino, alquilamino, dialquilamino, alcoxi, alquiltio (metiltio), carboxi libre o esterificado por un radical alquilo, carboxamida, CO-NH(alquil) y CO N(alquil)2, estando opcionalmente sustituidos todos los radicales alquilo, alcoxi y alquiltio; p y p' idénticos o diferentes representan respectivamente los numeros enteros 1 a 4 y 1 a 3; Ra se selecciona del grupo constituido por H; halogeno; CF3; hidroxi; OCF3; SO2- NH2; SO2-NH(alk), SO2-N(alk)2; mercapto; nitro; amino; NH(alk); N(alk)2; NH-OH; NH-CO-H; NH-CO-NH2; carboxi libre o esterificado por un radical alquilo que está él mismo opcionalmente sustituido; CN; CO-NH2; Y-(CH2)n-alquilo; Y-(CH2)n-cicloalquilo, Y-(CH2)n-heterocicloalquilo, Y-(CH2)n- arilo o Y-(CH2)n-heteroarilo, en los cuales Y representa un enlace sencillo o bien =O, S, NH, O-C(O), C(O)-NH, -C(O)N(CH3)-; CO; NH-C(O), NH-S(O) o NH-S(O)2; con n = O, 1 , 2, o 3 radicales en los cuales los radicales alquilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo están opcionalmente sustituidos, el radical cicloalquilo contiene de 3 a 10 miembros, el radical arilo contiene de 6 a 10 miembros, y los radicales heterocicloalquilo, y heteroarilo, opcionalmente sustituidos, contienen de 4 a 10 miembros de los cuales 1 a 4 son heteroátomos seleccionados entre O, S, N o NR3 en el cual R3 representa H o alquilo que está él mismo opcionalmente sustituido; estando todos los radicales alquilo, alcoxi, alquiltio, cicloalquilo, heterocicloalquilo, arilo y heteroarilo de los sustituyentes de los productos de la formula (1) opcionalmente sustituidos; estando dichos productos de la formula (1) en todas las formas de tautomeros e isomeros posibles; racémicos, enantiomeros y diastereoisomeros, así como las sales de adicion con los ácidos minerales y orgánicos o con las bases minerales y orgánicos de dichos productos de la formula (1).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0505037A FR2885904B1 (fr) | 2005-05-19 | 2005-05-19 | Nouveaux derives du fluorene, compositions les contenant et utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054125A1 true AR054125A1 (es) | 2007-06-06 |
Family
ID=36036699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101980A AR054125A1 (es) | 2005-05-19 | 2006-05-17 | Derivados del fluoreno, composiciones farmaceuticas que los contienen y su utilizacion en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de la proteina hsp90 |
Country Status (31)
Country | Link |
---|---|
US (1) | US7674795B2 (es) |
EP (1) | EP1888579B1 (es) |
JP (1) | JP4964874B2 (es) |
KR (1) | KR101288696B1 (es) |
CN (1) | CN101203518B (es) |
AR (1) | AR054125A1 (es) |
AT (1) | ATE518859T1 (es) |
AU (1) | AU2006248825B2 (es) |
BR (1) | BRPI0611424A2 (es) |
CA (1) | CA2608378C (es) |
CR (1) | CR9515A (es) |
DO (1) | DOP2006000112A (es) |
EA (1) | EA019027B1 (es) |
FR (1) | FR2885904B1 (es) |
GT (1) | GT200600206A (es) |
HN (1) | HN2006018410A (es) |
IL (1) | IL187163A (es) |
JO (1) | JO2753B1 (es) |
MA (1) | MA29493B1 (es) |
MX (1) | MX2007014443A (es) |
MY (1) | MY149037A (es) |
NO (1) | NO20076460L (es) |
NZ (1) | NZ563239A (es) |
PA (1) | PA8675701A1 (es) |
PE (1) | PE20061367A1 (es) |
TN (1) | TNSN07389A1 (es) |
TW (1) | TWI386406B (es) |
UA (1) | UA93203C2 (es) |
UY (1) | UY29549A1 (es) |
WO (1) | WO2006123061A2 (es) |
ZA (1) | ZA200709856B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1937643T3 (en) | 2006-03-16 | 2016-10-10 | Second Genome Inc | Bicycloheteroarylforbindelser som p2x7-modulatorer og anvendelser deraf |
FR2907453B1 (fr) * | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
US8759819B2 (en) * | 2007-11-22 | 2014-06-24 | Idemitsu Kosan Co., Ltd. | Organic electroluminescence device |
JP5794912B2 (ja) * | 2008-03-31 | 2015-10-14 | カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ | 供与体−受容体フルオレン骨格、それの方法及び使用 |
GB0809314D0 (en) * | 2008-05-22 | 2008-07-02 | Summit Corp Plc | Compounds for treating muscular dystrophy |
US8362268B2 (en) | 2008-05-30 | 2013-01-29 | University Of Notre Dame Du Lac | Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria |
FR2932484B1 (fr) | 2008-06-16 | 2010-06-18 | Sanofi Aventis | Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation |
EP2307342B1 (en) * | 2008-07-02 | 2017-06-21 | British Columbia Cancer Agency Branch | Diglycidic ether derivative therapeutics and methods for their use |
AR074797A1 (es) | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial |
AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
JP5940982B2 (ja) | 2010-01-06 | 2016-06-29 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲンレセプター活性調節因子としての、ビスフェノール誘導体およびその使用 |
US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
WO2012145330A1 (en) * | 2011-04-18 | 2012-10-26 | The University Of British Columbia | Fluorene-9-bisphenol compounds and methods for their use |
CN102442973A (zh) * | 2011-09-22 | 2012-05-09 | 华东理工大学 | 催化氧化伯醇闭环合成苯并咪唑和苯并噻唑化合物的方法 |
GB2515909B (en) * | 2012-01-31 | 2020-07-15 | Cambridge Display Tech Ltd | Composition comprising a fluorescent light-emitting material and triplet-accepting polymer and use thereof |
US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
NZ702169A (en) | 2012-05-25 | 2016-10-28 | Berg Llc | The use of heat shock protein 90 (hsp90) modulators for the treatment of metabolic syndrome |
RU2664532C2 (ru) | 2013-03-15 | 2018-08-20 | Джапан Тобакко Инк. | Пиразоламидное соединение и его применения в медицине |
PE20160091A1 (es) | 2013-05-10 | 2016-03-03 | British Columbia Cancer Agency Branch | Derivados de ester de moduladores del receptor de androgeno y metodos para su uso |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
EP3044197B1 (en) | 2013-09-09 | 2018-11-07 | British Columbia Cancer Agency Branch | Halogenated compounds for cancer imaging and treatment and methods for their use |
KR102280686B1 (ko) | 2014-02-11 | 2021-07-22 | 삼성전자주식회사 | 카바졸계 화합물 및 이를 포함한 유기 발광 소자 |
KR20220101015A (ko) * | 2014-04-14 | 2022-07-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
EP3152307A4 (en) | 2014-06-06 | 2018-05-02 | Berg LLC | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
US11426386B2 (en) | 2014-12-05 | 2022-08-30 | Case Western Reserve University | Compositions and methods of modulating S-nitrosylation |
WO2016090373A1 (en) | 2014-12-05 | 2016-06-09 | Case Western Reserve University | Compositions and methods of modulating s-nitrosylation |
JP6884100B2 (ja) | 2015-01-13 | 2021-06-09 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | がんの画像化及び治療用のヘテロ環式化合物ならびにそれらの使用方法 |
WO2016141458A1 (en) | 2015-03-12 | 2016-09-15 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
KR102691931B1 (ko) * | 2015-06-04 | 2024-08-05 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드계 조절인자 및 관련된 이용 방법 |
US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
CN114716377A (zh) | 2016-07-29 | 2022-07-08 | 日本烟草产业株式会社 | 吡唑-酰胺化合物的制造方法 |
CA3076889A1 (en) | 2017-09-25 | 2019-03-28 | Case Western Reserve University | Compositions and methods of reducing serum cholesterol and pcsk9 |
WO2019226991A1 (en) | 2018-05-25 | 2019-11-28 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
WO2020005938A1 (en) | 2018-06-25 | 2020-01-02 | Case Western Reserve University | Compositions and methods for treating tissue injury |
EP3852750A4 (en) | 2018-09-21 | 2022-05-11 | Case Western Reserve University | ALDOKETO REDUCTAE INHIBITORS AND THEIR USES |
WO2020081999A1 (en) | 2018-10-18 | 2020-04-23 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
CN109574917B (zh) * | 2018-12-03 | 2020-12-08 | 武汉尚赛光电科技有限公司 | 一种芴酮衍生物及其制备和应用 |
CA3125350A1 (en) | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Irreversible inhibitors of menin-mll interaction |
WO2020142559A1 (en) | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Inhibitors of menin-mll interaction |
WO2020198712A1 (en) | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
CN110981795B (zh) * | 2019-12-18 | 2021-02-12 | 武汉世纪久海检测技术有限公司 | 一种利用2-氰基异烟酸甲酯制备2-氨酰基异烟酸的方法 |
AU2021255723A1 (en) | 2020-04-17 | 2022-12-08 | Essa Pharma, Inc. | Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof |
IL310717A (en) | 2021-08-20 | 2024-04-01 | Biomea Fusion Inc | Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6015796A (en) * | 1995-06-14 | 1997-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
WO2002014315A2 (en) * | 2000-08-14 | 2002-02-21 | Ortho Mcneil Pharmaceutical, Inc. | Substituted pyrazoles |
JP4399265B2 (ja) * | 2001-12-21 | 2010-01-13 | ヴァーナリス(ケンブリッジ)リミテッド | 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
AU2003301226A1 (en) * | 2002-12-20 | 2004-07-22 | Pharmacia Corp | Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
WO2004072081A1 (en) * | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
DK1611112T3 (da) | 2003-02-11 | 2012-11-19 | Cancer Res Inst | Isoxazolforbindelser som hæmmere af varmechokproteiner |
GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
US7538224B2 (en) * | 2003-06-27 | 2009-05-26 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90 family protein inhibitors |
NZ546044A (en) | 2003-08-29 | 2009-09-25 | Vernalis Cambridge Ltd | Pyrimidothiophene compounds |
GB0323810D0 (en) * | 2003-10-10 | 2003-11-12 | Cancer Rec Tech Ltd | Pyridothiophene compounds |
US7538241B2 (en) * | 2003-12-26 | 2009-05-26 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90 family protein inhibitors |
FR2884252B1 (fr) * | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
-
2005
- 2005-05-19 FR FR0505037A patent/FR2885904B1/fr not_active Expired - Fee Related
-
2006
- 2006-05-12 DO DO2006000112A patent/DOP2006000112A/es unknown
- 2006-05-14 JO JO2006135A patent/JO2753B1/en active
- 2006-05-17 PE PE2006000520A patent/PE20061367A1/es not_active Application Discontinuation
- 2006-05-17 AR ARP060101980A patent/AR054125A1/es not_active Application Discontinuation
- 2006-05-17 HN HN2006018410A patent/HN2006018410A/es unknown
- 2006-05-18 MY MYPI20062304A patent/MY149037A/en unknown
- 2006-05-18 GT GT200600206A patent/GT200600206A/es unknown
- 2006-05-18 PA PA20068675701A patent/PA8675701A1/es unknown
- 2006-05-19 MX MX2007014443A patent/MX2007014443A/es active IP Right Grant
- 2006-05-19 UA UAA200714230A patent/UA93203C2/ru unknown
- 2006-05-19 JP JP2008511754A patent/JP4964874B2/ja not_active Expired - Fee Related
- 2006-05-19 WO PCT/FR2006/001137 patent/WO2006123061A2/fr not_active Application Discontinuation
- 2006-05-19 KR KR1020077029644A patent/KR101288696B1/ko not_active IP Right Cessation
- 2006-05-19 EA EA200702531A patent/EA019027B1/ru unknown
- 2006-05-19 UY UY29549A patent/UY29549A1/es unknown
- 2006-05-19 CA CA2608378A patent/CA2608378C/fr not_active Expired - Fee Related
- 2006-05-19 EP EP06755509A patent/EP1888579B1/fr active Active
- 2006-05-19 NZ NZ563239A patent/NZ563239A/en not_active IP Right Cessation
- 2006-05-19 TW TW095117762A patent/TWI386406B/zh not_active IP Right Cessation
- 2006-05-19 AU AU2006248825A patent/AU2006248825B2/en not_active Ceased
- 2006-05-19 BR BRPI0611424-5A patent/BRPI0611424A2/pt not_active IP Right Cessation
- 2006-05-19 CN CN2006800219737A patent/CN101203518B/zh not_active Expired - Fee Related
- 2006-05-19 AT AT06755509T patent/ATE518859T1/de not_active IP Right Cessation
-
2007
- 2007-10-18 TN TNP2007000389A patent/TNSN07389A1/en unknown
- 2007-11-05 IL IL187163A patent/IL187163A/en not_active IP Right Cessation
- 2007-11-13 CR CR9515A patent/CR9515A/es unknown
- 2007-11-14 US US11/939,735 patent/US7674795B2/en active Active
- 2007-11-15 ZA ZA2007/09856A patent/ZA200709856B/en unknown
- 2007-11-29 MA MA30431A patent/MA29493B1/fr unknown
- 2007-12-14 NO NO20076460A patent/NO20076460L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054125A1 (es) | Derivados del fluoreno, composiciones farmaceuticas que los contienen y su utilizacion en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de la proteina hsp90 | |
AR055606A1 (es) | Derivados de benzoquinazolina | |
AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
CY1118191T1 (el) | Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης | |
CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
CL2004000174A1 (es) | Compuestos derivados de malonamida n,n'-disustituidos; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la enfermedad de alzheimer. | |
NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
AR040257A1 (es) | Profarmacos de aminoacidos excitadores | |
AR033306A1 (es) | Compuestos | |
EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
RU2004122916A (ru) | Производные 6-фторбицикло [3.1.0]гексана | |
CN102260188A (zh) | 有机化合物 | |
CY1105301T1 (el) | Αρυλοσυμπυκνωμενες αζαπολυκυκλικες ενωσεις | |
NO20071137L (no) | Nye piperidinderivater for behandling av depresjon | |
MA32206B1 (fr) | Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation | |
CY1108529T1 (el) | Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν | |
EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
BRPI0409110A (pt) | derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer | |
AR066972A1 (es) | Derivados azapeptidicos | |
CY1111517T1 (el) | Παραγωγα 1,3-δ1υδροιμιδαζολο-2-θειονης ως αναστολεις της ντοπαμινης-βητα-υδροξυλασης | |
AR053082A1 (es) | DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS. | |
AR043485A1 (es) | Derivados del 8'-piridinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona y 8´-pirimidinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona substituidos | |
RU2007128080A (ru) | Производные пирролидиния в качестве мускариновых рецепторов мз | |
PA8573501A1 (es) | Derivados de benzoxazina y su empleo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |